Ketamine for PTSD: How the Treatment Works and Its Effects

Ketamine reduces PTSD symptoms rapidly, often within hours of the first dose, by blocking a specific receptor in the brain that governs how fear memories are stored and processed. In randomized trials, a single intravenous infusion produced meaningful symptom relief within 24 hours, and repeated infusions over two weeks led to response rates above 60 percent. The treatment is not yet approved specifically for PTSD, but the clinical evidence has grown steadily, and the drug is increasingly used off-label in specialized clinics alongside its FDA-approved nasal spray cousin, esketamine.

What Ketamine Does in the Brain

PTSD involves fear memories that get stuck. Under normal conditions, the brain gradually weakens the emotional charge of a scary memory each time you recall it safely, a process called fear extinction. In PTSD, that process stalls. The alarm system stays locked on, and the memory keeps triggering the same panic, hypervigilance, and avoidance it did originally.

Ketamine works primarily by blocking a receptor called NMDA, which plays a central role in how nerve cells communicate and form new connections. By doing so, it modulates excitatory signaling and synaptic plasticity, the brain’s ability to rewire itself in response to experience.¹ That rewiring is exactly what seems to go wrong in PTSD, and it appears to be exactly what ketamine can restart.

Animal research has filled in more detail. In rats exposed to a stress model designed to mimic PTSD, ketamine reversed both fear-related behavior and spatial memory problems by boosting a growth factor called BDNF in the hippocampus and amygdala, two brain regions heavily involved in fear processing.² Separate work in mice showed that ketamine can facilitate fear memory extinction and restore the electrical signaling needed for that process to work.³ There is also evidence that ketamine disrupts reconsolidation of established fear memories, essentially weakening them when they are pulled back into active recall, while upregulating BDNF in prefrontal regions that help put the brakes on fear responses.⁴

The practical upshot: ketamine seems to open a window in which the brain can do the rewiring that PTSD has been preventing. Fear memories become more accessible and, with the right conditions, more modifiable. That is a fundamentally different approach from the selective serotonin reuptake inhibitors (SSRIs) that remain the standard first-line pharmacotherapy for PTSD, which work on a slower timescale and through a different chemical system entirely.

What the Clinical Trials Show

The first rigorous randomized controlled trial of ketamine for PTSD, published in 2014, compared a single intravenous infusion of ketamine to a control infusion of the sedative midazolam (chosen because it mimics some of ketamine’s sedating effects, making it harder for participants to guess which drug they got). Twenty-four hours after infusion, people who received ketamine had significantly lower PTSD symptom scores, with a mean difference of about 13 points on a standard symptom scale.⁵ That is a clinically meaningful drop, not just a statistical blip.

A follow-up trial by the same research group tested what happens with repeated dosing. Participants received six infusions over two weeks, and by the end, two-thirds of those in the ketamine group qualified as treatment responders, compared with only one in five in the midazolam group. The average difference in symptom scores between the two groups was nearly 12 points, and the effect size was large.⁶

A systematic review and meta-analysis pooling data from multiple studies confirmed the pattern. Ketamine significantly reduced scores on the two most widely used PTSD measures at follow-up points ranging from one day to four weeks after treatment. The analysis also found that ketamine extended the time before PTSD symptoms returned compared to control treatment, by roughly two weeks on average.⁷ A separate meta-analysis confirmed statistically significant improvements in PTSD checklist scores at the endpoint of treatment courses lasting one to four weeks.⁸

These are still relatively small studies, and the research base is thinner than what exists for ketamine in depression. But the direction of the evidence is consistent, and the speed of onset sets ketamine apart from existing PTSD medications, which typically take weeks to show an effect.

How Long Relief Lasts

Speed is ketamine’s selling point, but durability is its weakness. After a single infusion, meaningful relief begins within hours and tends to peak within a day or two. But it does not last indefinitely. Among responders in the repeated-infusion trial, the median time before symptoms crept back was about four weeks after the two-week course of infusions ended.⁹ That is encouraging in the sense that relief outlasted the infusion schedule, but it means most people will need some kind of maintenance strategy.

Case reports offer a glimpse of what longer-term use can look like. One case described a man with chronic PTSD and suicidal thoughts who received nine infusions spread across 18 months, with significant and sustained improvement throughout.¹⁰ That kind of intermittent, long-term use may end up being how ketamine is deployed in practice, but the optimal schedule is not yet established.

Side Effects and Safety

Ketamine is not a gentle drug. It was developed as an anesthetic in the 1960s, and at the sub-anesthetic doses used for psychiatric treatment, it still produces noticeable effects during and shortly after infusion.¹¹ People commonly feel dissociated, floaty, or detached from their body. Some experience visual distortions or a dreamlike state. These effects are temporary and usually resolve within a couple of hours, but they can be unsettling, especially for someone whose PTSD already involves dissociative symptoms.

Meta-analytic data from PTSD trials specifically showed that ketamine caused more dry mouth, dizziness, and blurred vision than control treatment, with the odds of experiencing these side effects being several times higher than with placebo.⁷ These are uncomfortable but transient.

The cardiovascular side effects deserve more attention. Ketamine can cause temporary spikes in blood pressure and heart rate. In people with preexisting hypertension or heart conditions, this requires careful monitoring. Prolonged or frequent use raises additional concerns including potential cognitive effects on memory and concentration, as well as the risk of tolerance and dependence.¹² These risks are dose-dependent and more relevant to recreational misuse or chronic high-dose use than to supervised clinical infusions, but they are real and part of why ketamine treatment takes place in monitored clinical settings rather than being prescribed for home use.

One common misconception is that ketamine treatment feels like a recreational “K-hole.” The doses used for PTSD are sub-anesthetic, typically much lower than what would produce the profound dissociation associated with recreational abuse. Most patients describe the experience as unusual but tolerable. Still, clinics screen for a history of substance use disorders, and the dissociative effects are a reason ketamine therapy requires on-site supervision.

Who Benefits Most

The research so far has looked at several distinct patient groups. Some trials enrolled people with chronic PTSD who had already failed at least two antidepressant medications and had undergone cognitive behavioral therapy for a minimum of six months without adequate relief. Others focused on military veterans with combat-related PTSD or patients who had both PTSD and treatment-resistant depression.⁸ In other words, the evidence base is weighted toward people for whom standard treatments have already failed. This is both the drug’s most promising niche and a limitation, since we know less about how it performs as a first-line option.

Veterans represent a population of particular interest. In a retrospective case series of veterans with both treatment-resistant depression and PTSD who received intranasal esketamine (the FDA-approved nasal spray form), PTSD symptom scores dropped by an average of about 15 points over the induction phase. Roughly half showed a clinically meaningful PTSD response, even though only about 14 percent met the bar for a meaningful depression response during the same period.¹³ That dissociation between the PTSD and depression outcomes is interesting. It suggests ketamine may target PTSD symptoms through pathways that are at least partially independent of its antidepressant effect.

A larger real-world study examining patients with treatment-resistant depression found that those with comorbid PTSD improved just as much on depression measures as those without PTSD, and the PTSD symptoms themselves also improved significantly across all symptom clusters.¹⁴ This is reassuring because comorbid PTSD can make depression harder to treat with conventional medications, and it suggests ketamine may be useful precisely in patients who tend to be non-responders to standard care.

Pairing Ketamine With Psychotherapy

One of the more intriguing developments is the idea of using low-dose ketamine not as a standalone treatment but as a tool to enhance psychotherapy. The logic follows directly from the mechanism: if ketamine opens a window of enhanced neuroplasticity and makes fear memories more accessible and modifiable, then doing trauma-focused therapy during that window might produce deeper and more lasting changes than either treatment alone.

A newer approach called Ketamine Assisted EMDR Therapy combines low-dose sublingual ketamine with EMDR, a well-established trauma therapy that involves guided eye movements while recalling distressing memories. The idea is that ketamine reduces hyperarousal, improves access to traumatic memories, and enhances the brain’s ability to adaptively reconsolidate those memories during the reprocessing that EMDR facilitates.¹⁵ This is still early-stage research, but it represents a philosophically different approach: rather than using ketamine to suppress symptoms, it uses ketamine to amplify the therapeutic work that might resolve them.

Whether combining ketamine with prolonged exposure therapy or cognitive processing therapy would yield similar benefits is an open question. Some clinicians already informally time therapy sessions to coincide with the days following a ketamine infusion, when patients report feeling more emotionally flexible and less avoidant. Formal trials testing these combinations for PTSD are underway but have not yet reported large-scale results.

The Cost and Access Problem

Even as the evidence grows, practical barriers keep ketamine out of reach for many of the people who might benefit most. The FDA has approved esketamine (marketed as Spravato) as a nasal spray for treatment-resistant depression, but it has not been approved for PTSD, meaning its use for trauma-related symptoms is off-label. Generic intravenous ketamine is far cheaper but is also off-label for any psychiatric indication, and most insurance plans do not cover it.

The financial gap between the two forms is dramatic. An eight-treatment course of intranasal esketamine costs roughly $6,000, compared to about $650 for intramuscular ketamine, with the price difference driven almost entirely by the branded nasal spray itself.¹⁶ And even the cheaper option adds up when you factor in the requirement for clinical supervision during and after each dose, plus the cost of the clinician’s time, monitoring equipment, and follow-up care.

Data on who actually receives ketamine treatment tells a stark story. The patients who access this care tend to belong to higher income brackets, and out-of-pocket payment is the most common way treatment gets funded. Insurance reimbursement for esketamine exists in theory but is often time-consuming and uncertain to secure, while off-label IV ketamine is typically not covered at all.¹⁷ This creates an uncomfortable situation in which a drug that shows particular promise for veterans and people with severe, treatment-resistant PTSD is most accessible to people with high disposable income.

Predicting Who Will Respond

Not everyone with PTSD benefits from ketamine. Across the trials, roughly a third of participants in the ketamine groups did not meet criteria for treatment response. That non-response rate, combined with the cost, side effects, and time commitment of repeated infusions, creates a strong incentive to figure out in advance who is likely to benefit.

Recent research has taken an early but promising step in that direction. Using blood samples collected before treatment from participants in a ketamine-for-PTSD clinical trial, researchers applied machine learning to patterns in DNA methylation, a type of chemical modification that affects how genes are read without changing the DNA sequence itself. A model built on about 1,200 of these methylation markers, combined with clinical information, was able to distinguish eventual responders from non-responders with roughly 93 percent accuracy. The relevant markers clustered near genes involved in glutamate signaling (the same system ketamine acts on) and immune regulation, as well as genes already implicated as risk factors for PTSD.¹⁸

This is a single study and the findings need replication in larger, independent samples before anyone starts ordering blood tests to guide prescribing. But it represents the direction the field is heading: away from trial-and-error prescribing and toward matching treatments to individual biology. If a simple blood draw could reliably predict whether ketamine would work for a given person, it would save non-responders from unnecessary side effects and expense, and it would strengthen the case for covering ketamine under insurance for those most likely to benefit. For a treatment that currently sits in a strange regulatory limbo, widely available yet not formally indicated for the condition it treats most rapidly, that kind of precision could make a meaningful difference in how quickly the research translates into routine care.